DOCSLIB.ORG

A Systemic Non-Lytic State and Localthrombolytic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Systemic Non-Lytic State and Localthrombolytic Br Heart J 1990;64:355-8 355 Br Heart J: first published as 10.1136/hrt.64.6.355 on 1 December 1990. Downloaded from ORIGINAL ARTICLES A systemic non-lytic state and local thrombolytic failure of anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC) in acute myocardial infarction Johan Brugemann, Jan van der Meer, Bert H Takens, Hans Hillege, Kong I Lie Abstract changes in haematological variables such as The relation between coronary throm- fibrinogen, plasminogen, and a2 antiplasmin bolysis and coagulation variables after during the first 24 hours after they were administration of anistreplase (anisoy- given.' These changes were ascribed to lated plasminogen streptokinase activator systemic effects. Some patients, however, complex, APSAC) was studied in showed no substantial decrease in plasma patients with an acute myocardial in- fibrinogen after anistreplase or streptokinase farction. Fifty eight consecutive patients administration.7 This suggests resistance to with acute myocardial infarction were these drugs. It has been suggested that a given 30 U of anistreplase intravenously systemic lytic state, defined as a low plasma within 4 hours of the onset of symptoms. concentration of fibrinogen after thrombolytic A fall in the plasma concentration fib- treatment, is a prerequisite for local thrombo- rinogen to < 10 g/l 90 minutes after lytic efficacy.8 was con- To investigate the possibility of drug administration of anistreplase copyright. sidered to reflect a systemic lytic state. resistance as an explanation for failure of Coronary angiography was performed 48 thrombolytic treatment, we performed a hours after thrombolytic treatment. The retrospective study to assess the relation overall patency rate was 74% (43/58). between the systemic fibrinolytic effects and Patency rates were significantly dif- the local efficacy of anistreplase in patients ferent in patients with a systemic lytic with acute myocardial infarction. (83% (43/52)) and a systemic non-lytic state (0% (0/6)). The absence of a sys- http://heart.bmj.com/ temic lytic state after anistreplase Patients and methods administration seemed to be highly PATIENTS predictive of the failure of coronary We studied 58 consecutive patients (47 men, 11 thrombolysis. Coagulation studies women), mean age 57 years (range 34-71), who showed evidence of inhibition of anistre- presented within 4 hours of the onset of chest plase induced fibrinolytic activity which pain. Selection criteria for thrombolytic treat- may explain the failure of thrombolytic ment included the presence of characteristic treatment in patients with evidence of a symptoms of myocardial infarction and ST state. segment elevation of at least 0 1 mV in one or systemic non-lytic on September 27, 2021 by guest. Protected more of the standard leads or at least 0-2 mV in Department of precordial leads in a 12 Cardiology, two or more of the University of Thrombolytic drugs reduced mortality in lead electrocardiogram and the presence of Groningen, The patients with acute myocardial infarction symptoms unresponsive to sublingual glyceryl Netherlands treated within 6, 12, or even 24 hours of the trinitrate. We excluded patients with contra- J Brugemann L H Takens onset of symptoms.1 When treatment was indications for thrombolytic treatment and H Hillege started within the first 4-6 hours after the those who had been treated with streptokinase K I Lie onset of chest pain, reperfusion was shown in or anistreplase within the previous 6 months. Department of most the infarct related coronary arteries. Hematology, of University of However, in up to 30-40% of the patients no STUDY PROTOCOL Groningen, The reperfusion could be achieved.4 Failure of Patients were treated with 30 U of anistreplase Netherlands thrombolytic treatment has been reported (Eminase, SmithKline Beecham) administered J van der Meer irrespective of the drug used.4 The con- intravenously in 4-5 minutes. Infusion with Correspondence to an heparin (30 000 U in 24 hours) was started 4-6 Dr Johan Brugemann, figuration of coronary obstruction may be Department of Cardiology, important determinant of the success of treat- hours after thrombolytic treatment and was Thoraxcentre University continued until an adequate level of anti- Hospital Groningen, ment,5 but inhibition of drug activity has Oostersingel 59, 9713 EZ never been ruled out. coagulation had been achieved with oral acen- Groningen, The In general, streptokinase and anistreplase ocoumarol, which was started after 48-72 Netherlands. hours. To assess patency of the infarct related Accepted for publication (anisoylated plasminogen streptokinase acti- 31 July 1990 vator complex, APSAC) caused comparable artery, coronary angiography was performed 356 Brugemann, van der Meer, Takens, Hillege, Lie Br Heart J: first published as 10.1136/hrt.64.6.355 on 1 December 1990. Downloaded from 48 hours (range 36-60) after the administration patients showing a systemic lytic state and a of anistreplase in all patients. In the first 30 systemic non-lytic state were performed by consecutive patients patency was also assessed means of Student's t test for independent after 90 minutes (range 1 to 3 hours). Patency samples. Comparisons within the groups were was documented according to the score used in made with the paired Student's t test. the thrombolysis in myocardial infarction Measurements of reptilase time, euglobulin (TIMI) trial.9 Scores of grade 0 or 1 indicated clot lysis time, and fibrinogen/fibrin degrada- occlusion of the infarct related vessel and tion products were expressed as median grades 2 and 3 patency. (range). Patient groups were compared by the Mann-Whitney U/Wilcoxon rank sum test. COAGULATION ANALYSES Differences within the groups were tested by Coagulation and fibrinolytic variables were the Wilcoxon matched paired signed ranks test. studied immediately before and 90 minutes and We used Fisher's exact test to compare the 48 hours after anistreplase administration. result of treatment in terms of patency and the Venous blood samples were collected on ice in a presence of a systemic lytic state. A two tailed p 1/10 volume 3 05% trisodium citrate for value of <0-05 was regarded as statistically measurements of fibrinogen, plasminogen, a2 significant. antiplasmin, reptilase time, and euglobulin clot lysis time. Assays were performed immediately or plasma was stored at - 80°C for analysis Results later. Fibrinogen was measured according to COAGULATION DATA the method of Clauss. " Plasminogen and a2 Fifty eight patients were retrospectively antiplasmin assays were performed with a syn- classified into two groups. Fifty two showed a thetic chromogenic substrate (Kabi) according systemic fibrinolytic state and in six patients to the method of Friberger et al.'1 Reptilase plasma fibrinogen concentrations did not time was determined by the method of Soria et decrease below 1 0 g/l. Initial values of fibrin- al 12 and euglobulin clot lysis times by the ogen, plasminogen, a2 antiplasmin, reptilase method of Buckell.'3 The assay for fibrinogen/ time, euglobulin clot lysis time, and fibrinogen/ fibrin degradation products was carried out on fibrin degradation products were similar in the serum collected at the times mentioned above two groups (table 1). with a latex agglutination kit (Wellcome) After 90 minutes, fibrinogen, plasminogen, according to the method of Pitcher.'4 and a2 antiplasmin concentrations were A systemic lytic state was defined as a significantly reduced in both the lytic and non- decrease of the plasma concentration of lytic groups. Mean plasma concentrations ofcopyright. fibrinogen to below 1 0 g/l, measured 1-5 hours fibrinogen in the lytic and the non-lytic groups after the administration of anistreplase. were 0-0 g/l and 2-3 g/l (normal range 1-7-3-5); of plasminogen 11% and 57% (normal range STATISTICAL ANALYSIS 70-130); and of a2 antiplasmin 4% and 35% Plasma concentrations of fibrinogen, plas- (normal range 90-130) respectively. These minogen, and a2 antiplasmin were expressed as differences were statistically significant. mean (SD). Statistical comparisons between Individual values for fibrinogen in the six non- http://heart.bmj.com/ lytic patients before and 90 minutes after treatment with anistreplase were: 3-3 v 2-7; 2 7 Table 1 Coagulation variables of all patients stratified according tofibrinolytic state v 23; 24v 1 1; 3v 22; 24 v 1-8, and 37v 3-6 g/l respectively. The reptilase time was Variable Lytic Non-lytic p value$ considerably prolonged in the lytic group from Fibrinogen (g/l): 19 to 109 seconds but did not change in the Before 3-1 (0-96) 2-9 (0-48) NS non-lytic group (19 v 24 seconds). Euglobulin 90 minutes after 0.0 (0-15)* 2-3 (0-78)t <0-01 48 h after 2-5 (0-68)* 4-2 (0-84) <0-01 clot lysis time was shortened from > 120 before to < 10 minutes after the administration of Plasminogen (%): on September 27, 2021 by guest. Protected Before 97 (18) 104 (6) NS anistreplase in both groups (normal value 90 min after 11(13)* 57 (9)* <0-01 > 120 minutes). Serum concentrations of 48 h after 55 (13)* 78 (12)t < 0-01 fibrinogen/fibrin degradation products a, antiplasmin () remained within normal ranges (< 8 in Before 93 (14) 90 (12) NS Mg/ml) 90 min after 4 (5)* 35 (2)t < 0-01 the non-lytic group, whereas they were con- 48 h after 80 (16)* 99 (8) <0-01 siderably increased in the lytic group (median Reptilase time (s): value >256 Mg/ml). Before 19 (10-27) 19 (18-20) NS These changes declined after 48 hours. At 90 min after 109 (44-201)* 24 (18-31) <0-01 48 h after 19 (15-23) 20 (19-21) NS that time mean plasma concentrations offibrin- ogen, plasminogen, and a2 antiplasmin were Euglobulin clot lysis time (min): still significantly lower in the lytic group, and, Before > 120 (> 120) > 120 (> 120) NS with the exception of fibrinogen, below the 90minafter <10(<10)* <10(<10-15)t NS 48 h after > 120 (95->120) > 120 (> 120) NS normal ranges.
Load more

Recommended publications
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Malik2018.Pdf
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Nat Genet Manuscript Author . Author manuscript; Manuscript Author available in PMC 2018 May 25. Published in final edited form as: Nat Genet. 2018 April ; 50(4): 524–537. doi:10.1038/s41588-018-0058-3. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes A full list of authors and affiliations appears at the end of the article. Abstract Stroke has multiple etiologies, but the underlying genes and pathways are largely unknown. We conducted a multiancestry genome-wide-association meta-analysis in 521,612 individuals (67,162 cases and 454,450 controls) and discovered 22 new stroke risk loci, bringing the total to 32. We further found shared genetic variation with related vascular traits, including blood pressure, cardiac traits, and venous thromboembolism, at individual loci (n = 18), and using genetic risk scores and linkage-disequilibrium-score regression. Several loci exhibited distinct association and pleiotropy patterns for etiological stroke subtypes. Eleven new susceptibility loci indicate mechanisms not previously implicated in stroke pathophysiology, with prioritization of risk variants and genes accomplished through bioinformatics analyses using extensive functional datasets. Stroke risk loci were significantly enriched in drug targets for antithrombotic therapy. Stroke is the second leading cause of death and disability-adjusted life years worldwide1,2. Characterized by a neurological deficit of sudden onset, stroke is primarily caused by brain infarction (ischemic stroke) and, less often, by intracerebral hemorrhage (ICH). Common etiological subtypes of ischemic stroke include large-artery atherosclerotic stroke (LAS), cardioembolic stroke (CES), and stroke caused by small-vessel disease (small-vessel stroke (SVS)), which is also the leading cause of ICH.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Antithrombotic Agents in the Management of Sepsis
    Antithrombotic Agents in the Management of Sepsis !"#$ Loyola University Medical Center, Maywood, Illinois-60153, USA ABSTRACT Sepsis, a systemic inflammatory syndrome, is a response to infection and when associated with mul- tiple organ dysfunction is termed, severe sepsis. It remains a leading cause of mortality in the critically ill. The response to the invading bacteria may be considered as a balance between proinflammatory and antiinflammatory reaction. While an inadequate proinflammatory reaction and a strong antiinflammatory response could lead to overwhelming infection and death of the patient, a strong and uncontrolled pro- inflammatory response, manifested by the release of proinflammatory mediators may lead to microvas- cular thrombosis and multiple organ failure. Endotoxin triggers sepsis by releasing various mediators inc- luding tumor necrosis factor-alpha and interleukin-1(IL-1). These cytokines activate the complement and coagulation systems, release adhesion molecules, prostaglandins, leukotrienes, reactive oxygen speci- es and nitric oxide (NO). Other mediators involved in the sepsis syndrome include IL-1, IL-6 and IL-8; arachidonic acid metabolites; platelet activating factor (PAF); histamine; bradykinin; angiotensin; comp- lement components and vasoactive intestinal peptide. These proinflammatory responses are counterac- ted by IL-10. Most of the trials targeting the different mediators of proinflammatory response have failed due a lack of correct definition of sepsis. Understanding the exact pathophysiology of the disease will enable better treatment options. Targeting the coagulation system with various anticoagulant agents inc- luding antithrombin, activated protein C (APC), tissue factor pathway inhibitor (TFPI) is a rational appro- ach. Many clinical trials have been conducted to evaluate these agents in severe sepsis.
    [Show full text]
  • Cloning, Expression, and Renaturation Studies of Reteplase
    J. Microbiol. Biotechnol. (2003), 13(6), 989–992 Cloning, Expression, and Renaturation Studies of Reteplase 1 1,2 1 1 ZHAO, YOUCHUN , WANG GE , YANG KONG , AND CHANGKAI ZHANG 1State Key Laboratory of Microbial Technology, Shandong University, Jinan 250100, P.R. China 2Shandong Younglong Biotechnology Co., Jinan 250100, P.R. China Received: September 9, 2002 Accepted: July 4, 2003 Abstract Recombinant human tissue plasminogen activator deletion mutein (Reteplase, abbreviated as r-PA) represent deletion mutein (Reteplase) is a clinically promising thrombolytic one of the third generation thrombolytic drugs. Reteplase drug. Reteplase cDNA was subcloned into a bacteria expression manifests advantages in large-scale production, prolonged system, and the resultant recombinant was biologically half-time, thromobolytic potency, and fewer side effects, characterized. The Reteplase was expressed in Escherichia thus it attracts great attention from cardiovascular experts coli as an inclusion body, and the downstream processes of the [6, 16]. Reteplase inclusion body included denaturation, renaturation, Reteplase has been obtained by deleting the three and purification. A protein disulfide isomerase (PDI) was used structural domains of Kringle I, Finger, and EGF, while to assist the refolding of Reteplase, and it was found to increase retaining the thrombolytic Kringle II, protease domain, the refolding rate from less than 2% to more than 20%. The two functional regions of protease (amino acid residues refolded Reteplase was purified through two chromatography 176- 527), as well as the N-terminal 1 to 3 amino acid steps, including lysine-coupled agarose affinity chromatography residues [8, 10, 12, 17]. Reteplase expressed in Escherichia and then CM-sepharose cation-exchange chomatography.
    [Show full text]
  • Appendix C Medication Tables
    Appendix C Medication Tables Note: The medication tables are not meant to be inclusive lists of all available therapeutic agents. Approved medication tables will be updated regularly. Discrepancies must be reported. See Resource Section of this manual for additional contact information. Release Notes: Aspirin Table Version 1.0 Table 1.1 Aspirin and Aspirin-Containing Medications Acetylsalicylic Acid Acuprin 81 Alka-Seltzer Alka-Seltzer Morning Relief Anacin Arthritis Foundation Aspirin Arthritis Pain Ascriptin Arthritis Pain Formula ASA ASA Baby ASA Baby Chewable ASA Baby Coated ASA Bayer ASA Bayer Children's ASA Buffered ASA Children's ASA EC ASA Enteric Coated ASA/Maalox Ascriptin Aspergum Aspir-10 Aspir-Low Aspir-Lox Aspir-Mox Aspir-Trin Aspirbuf Aspircaf Aspirin Aspirin Baby Aspirin Bayer Aspirin Bayer Children's Aspirin Buffered Aspirin Child Aspirin Child Chewable Aspirin Children's Aspirin EC Aspirin Enteric Coated Specifications Manual for National Appendix C-1 Hospital Quality Measures Table 1.1 Aspirin and Aspirin-Containing Medications (continued) Aspirin Litecoat Aspirin Lo-Dose Aspirin Low Strength Aspirin Tri-Buffered Aspirin, Extended Release Aspirin/butalbital/caffeine Aspirin/caffeine Aspirin/pravachol Aspirin/pravastatin Aspirtab Bayer Aspirin Bayer Aspirin PM Extra Strength Bayer Children’s Bayer EC Bayer Enteric Coated Bayer Low Strength Bayer Plus Buffered ASA Buffered Aspirin Buffered Baby ASA Bufferin Bufferin Arthritis Strength Bufferin Extra Strength Buffex Cama Arthritis Reliever Child’s Aspirin Coated Aspirin
    [Show full text]
  • Drugs Affecting Coagulation
    PHARMACOLOGY Drugs affecting Learning objectives coagulation After reading this article, you should be able to: C outline the process of coagulation Balraj Appadu C compare and contrast the different drugs used for Katrina Barber anticoagulation C evaluate anticoagulant drugs and their uses in patients under- going surgery Abstract For more than half a century, heparin and vitamin K antagonists have defined anticoagulant therapy in both the short-term and long-term leading to dissolution (lysis) and restoration of blood flow to the management of thrombotic diseases. However, the limitations of organs. these traditional anticoagulants have prompted the development of new drugs. In the past 15 years new agents with improved safety pro- First-generation agents fi le and greater ease of use that target almost every step of the coag- Streptokinase is a non-enzymatic protein produced by b-hae- ulation cascade have been developed. These include factor Xa molytic streptococci. It activates the fibrinolytic system indi- inhibitors and direct thrombin inhibitors. The mechanism of action of rectly, binding to human plasminogen and forming a 1:1 ‘ ’ these new anticoagulants and also the older agents are reviewed in stoichiometric complex, which converts plasminogen into this article. plasmin. It is associated with allergic reactions and can stimulate Keywords ADP receptor antagonists; dabigatran; fondaparinux; the production of anti-streptococcal antibodies. For this reason, glycoprotein IIb/IIIa antagonists; heparin; rivaroxaban; warfarin repeat doses should be avoided. Urokinase is a trypsin-like serine protease composed of two Royal College of Anaesthetists CPD Matrix: A102 polypeptide chains connected by a disulphide bridge. It activates plasminogen directly, converting it to active plasmin.
    [Show full text]
  • Heparin TAP Report
    CFNP TAP Review Heparin 8/16/2002 HEPARIN Livestock Executive Summary Heparinic acid, or heparin, is highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but in humans it is used to prevent blood clotting in vivo and in vitro, in the form of many different salts. 1 The subject of the petition is a request for heparin to be approved for use in organic livestock medical treatment. Heparin is used in blood transfusions to prevent the donor’s blood from coagulating prior to administration, as well as in animals at risk of thrombosis due to endotoxemia and disseminated intravascular coagulopathy. Summary of TAP Reviewer Analyses 2 Synthetic/ Allow without restrictions? Allow only with restrictions? (See Reviewers’ Nonsynthetic comments for restrictions) Synthetic (3) Yes (1) No (2) No (2) Identification Chemical names: Heparin, Heparinic acid Other Names: Calcilean, Calciparine, Hepalean, Heparin Leo, Liquaemin Bemiparin, CY 216, CY 222, Certoparin, Clexane, Clivarin, Clivarine, Dalteparin, Enoxaparin, Eparina [DCIT], FR 860, Fluxum, Fragmin A, Fragmin B, Fraxiparin, Hed-heparin, Heparin CY 216, Heparin sulfate, Heparina [INN- Spanish], Heparinate, Heparine [INN-French], Heparinum [INN-Latin, Hepathrom, KB 101, Lipo-hepin, Liquemin, Multiparin, Novoheparin, OP 386, OP 622, Pabyrin, Parnaparin, Parvoparin, Pularin, Reviparin, Sandoparin, Sublingula, Thromboliquine, Vetren, Vitrum AB, alpha-Heparin, depo-Heparin CAS Number: #9005-49-6 Other numbers: EINECS #232-681-7 HSDB #3094 NIOSH: MI0700000 RTECS Number : MI0850000 1 “Heparin.” ChemID Plus. http://toxnet.nlm.nih.gov/cgi-bin/sis/search 2 This Technical Advisory Panel (TAP) review is based on the information available as of the date of this review.
    [Show full text]
  • Plasminogen-Streptokinase
    Drugs used in coagulation disorders 2019 Laszlo Köles [email protected] http://semmelweis.hu/pharmacology Basic principles of blood coagulation Normal (not damaged) vascular endothel - antithrombogenic Vascular injury initiates events leading to • vasospasm • platelet adhesion and aggregation - white thrombus • blood coagulation - red thrombus • fibrinolysis • cell proliferation, repair mechanisms Birth of a thrombus platelets tissue factor fibrin platelets + tissue factor platelets + fibrin platelets + fibrin + tissue factor Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest. 2005 DRUGS USED IN THROMBOEMBOLIC DISORDERS • Antiplatelet drugs • Anticoagulants • Fibrinolytics Antiplatelet drugs Thrombocytes I. Circulating platelets at rest - small, discoid anuclear cells Vascular injury - platelet adhesion, activation, aggregation collagen-contact - adhesion of platelets to surface glycoprotein Ib/IX - vWF, fibronectin, vitronectin, thrombospondin activation release reaction (e.g. ADP, serotonin) pseudopods (higher surface) synthesis of thromboxan A2 Thrombocytes II. Activators of thrombocytes collagen-contact agonists of the G-protein coupled surface receptors thrombin (PAR-1 receptor) ADP (P2Y1 and P2Y12 receptors) serotonin (5-HT2A receptor) epinephrine (2 receptor) Role of eicosanoids: thromboxane A2 prostacycline Aggregation of platelets GP IIb/IIIa receptor - binding to fibrinogen and other RGD proteins (-Arg-Gly-Asp e.g. vWF, vitronectin) - bridges between thrombocytes Antiplatelet drugs Mechanisms of
    [Show full text]
  • Core/Quality Measures Reference Sheet 07-01-16 Through 12-01-16 Discharges
    Core/Quality Measures Reference Sheet 07-01-16 through 12-01-16 Discharges CMS Expanded Measure Sets STROKE STROKE (This addresses both primary stroke diagnoses as Fibrinolytic Agents well as strokes that occur during hospitalization, i.e. post-op) • VTE Prohylaxis Abbokinase APSAC Streptokinase • Antithrombotics at discharge Activase Eminase Tenecteplase • Anticoagulation at discharge for atrial fibrillation Alteplase Kabikinase Tissue plasminogen • IV tPA (arrival 2 hr, treat 3 hr) Anistreplase Retavase Activator Anisoylated Plasminogen- Reteplase TNKase • Antithrombotic end of Day 2 Streptokinase Activator rPA (RPA) tPA (TPA) • Lipids drawn, treat with Statin prescribed at Discharge Complex Streptase • Patient receives stroke education which include: - Personable modifiable risk factors for stroke Anticoagulant Medications - Stroke - How to activate EMS for stroke - Stroke warning S&S Argatroban Enoxaparin Lovenox - Their prescribed medications - Need for F/U after discharge Arixtra Fondaparinux Pradaxa • Assessed for Rehab Coumadin Fragmin Refludan • Dysphagia screen prior to PO intake Dabigatran Heparin I.V. Rivaroxaban Dabigatran etexilate Innohep Tinzaparin VTE Dalteparin Jantoven Warfarin VTE 5 (Applies to patients diagnosed with confirmed VTE Lepirudan Warfarin Sodium that are discharged home on warfarin with written discharge Xarelto instructions that address all 4 criteria.) 1. Discharge instructions Address Compliance Issues (Include Warfarin all): Coumadin Warfarin • Taking warfarin as instructed Jantoven Warfarin Sodium
    [Show full text]
  • Healthy U Medical Pharmacy Prior Authorization List
    Below is the list of Medical Drug J‐codes that require pre‐service review for Healthy U Medicaid. Please submit the Medical Utilization Management Review form (select Medical Pharmacy from the drop down), attach all necessary clinical documentation and submit to the U of U Health Plans Pharmacy Team by either fax to 801‐213‐1547 or by email: [email protected] If you have questions or need assistance please call for: 801‐213‐4104; Toll Free 833‐981‐0212 CODE DESCRIPTION PA Status Notes 0537T Chimeric antigen receptor T‐cell (CAR‐T) therapy; harvesting of blood‐derived T lymphocytes for Not Covered development of genetically modified autologous CAR‐T cells, per day 0538T Chimeric antigen receptor T‐cell (CAR‐T) therapy; preparation of blood‐derived T lymphocytes for Not Covered transportation (eg, cryopreservation, storage) 0539T Chimeric antigen receptor T‐cell (CAR‐T) therapy; receipt and preparation of CAR‐T cells for Not Covered administration 0540T Chimeric antigen receptor T‐cell (CAR‐T) therapy; CAR‐T cell administration, autologous Not Covered A9513 Lutetium lu 177, dotatate, therapeutic, 1 millicurie PA Required A9589 Instillation, Hexaminolevulinate Hydrochloride, 100 mg PA Required B4164 Parenteral nutrition solution: carbohydrates (dextrose), 50% or less (500 ml = 1 unit) ‐ home mix PA Required B4168 Parenteral nutrition solution; amino acid, 3.5%, (500 ml = 1 unit) ‐ home mix PA Required B4172 Parenteral nutrition solution; amino acid, 5.5% through 7%, (500 ml = 1 unit) ‐ home mix PA Required B4176 Parenteral
    [Show full text]
  • INCB 18424-258 Protocol Amendment 2 and Agree to Conduct the Study As Outlined
    Incyte Corporation Page 1 of 92 Protocol INCB 18424-258 Amendment 2 09 AUG 2013 Clinical Study Protocol INCB 18424-258 / NCT01348490 An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-Myelofibrosis and Post Polycythemia Vera- Myelofibrosis Who Have Platelet Counts of 50 × 109/L to 100 × 109/L Product: Ruxolitinib IND Number: 77,456 Phase of Study: 2 Sponsor: Incyte Corporation Route 141 & Henry Clay Road Building E336 Wilmington, DE 19880 US Date of Protocol: 29 MAR 2011 Date of Protocol Amendment 1: 17 AUG 2011 Date of Protocol Amendment 2: 09 AUG 2013 This study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and conducted in adherence to the study protocol, Good Clinical Practices as defined in Title 21 of the US Code of Federal Regulations Parts 50, 54 56, 312, and Part 11 as well as ICH GCP consolidated guidelines (E6) and applicable regulatory requirements. The information in this document is confidential. No part of this information may be duplicated, referenced, or transmitted in any form or by any means (electronic, mechanical, photocopy, recording, or otherwise) without the prior written consent of Incyte Corporation. CONFIDENTIAL Incyte Corporation Page 2 of 92 Protocol INCB 18424-258 Amendment 2 09 AUG 2013 INVESTIGATOR'S AGREEMENT I have received and read the Investigator’s Brochure for ruxolitinib. I have read the INCB 18424-258 Protocol Amendment 2 and agree to conduct the study as outlined. I agree to maintain the confidentiality of all information received or developed in connection with this protocol.
    [Show full text]